key: cord-0853492-ylza6gz1
authors: Davis, David A.; Bulut, Haydar; Shrestha, Prabha; Yaparla, Amulya; Jaeger, Hannah K.; Hattori, Shin-ichiro; Wingfield, Paul T.; Mieyal, John J.; Mitsuya, Hiroaki; Yarchoan, Robert
title: Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300
date: 2021-08-17
journal: mBio
DOI: 10.1128/mbio.02094-21
sha: ad9b9b5ff6351f88f2d9209cbf1214d83398adb2
doc_id: 853492
cord_uid: ylza6gz1

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), encodes two proteases required for replication. The main protease (M(pro)), encoded as part of two polyproteins, pp1a and pp1ab, is responsible for 11 different cleavages of these viral polyproteins to produce mature proteins required for viral replication. M(pro) is therefore an attractive target for therapeutic interventions. Certain proteins in cells under oxidative stress undergo modification of reactive cysteines. We show M(pro) is susceptible to glutathionylation, leading to inhibition of dimerization and activity. Activity of glutathionylated M(pro) could be restored with reducing agents or glutaredoxin. Analytical studies demonstrated that glutathionylated M(pro) primarily exists as a monomer and that modification of a single cysteine with glutathione is sufficient to block dimerization and inhibit its activity. Gel filtration studies as well as analytical ultracentrifugation confirmed that glutathionylated M(pro) exists as a monomer. Tryptic and chymotryptic digestions of M(pro) as well as experiments using a C300S M(pro) mutant revealed that Cys300, which is located at the dimer interface, is a primary target of glutathionylation. Moreover, Cys300 is required for inhibition of activity upon M(pro) glutathionylation. These findings indicate that M(pro) dimerization and activity can be regulated through reversible glutathionylation of a non-active site cysteine, Cys300, which itself is not required for M(pro) activity, and provides a novel target for the development of agents to block M(pro) dimerization and activity. This feature of M(pro) may have relevance to the pathophysiology of SARS-CoV-2 and related bat coronaviruses.

IMPORTANCE SARS-CoV-2 is responsible for the devastating COVID-19 pandemic. Therefore, it is imperative that we learn as much as we can about the biochemistry of the coronavirus proteins to inform development of therapy. One attractive target is the main protease (M pro ), a dimeric enzyme necessary for viral replication. Most work thus far developing M pro inhibitors has focused on the active site. Our work has revealed a regulatory mechanism for M pro activity through glutathionylation of a cysteine (Cys300) at the dimer interface, which can occur in cells under oxidative stress. Cys300 glutathionylation inhibits M pro activity by blocking its dimerization. This provides a novel accessible and reactive target for drug development. Moreover, this process may have implications for disease pathophysiology in humans and bats. It may be a mechanism by which SARS-CoV-2 has evolved to limit replication and avoid killing host bats when they are under oxidative stress during flight. chromatography (RP-HPLC) analysis. The mass was confirmed by matrix-assisted laser desorption ionization2time of flight mass spectrometry (MALDI-TOF MS) analysis (see Fig. S1A to E in the supplemental material). M pro activity was measured utilizing a paranitroanilide (pNA) substrate (H2N-TSAVLQ-pNA) as described previously for SARS-CoV-1 M pro (21, 22) . To assess the effects of oxidized glutathione (GSSG) and reduced glutathione (GSH) on M pro , we treated M pro at concentrations of either 1.2 or 18 mM with 2 mM or 10 mM GSSG or GSH for 30 min at 37°C and then measured M pro activity at 1 mM concentration for each treated sample. Previous reports have indicated that the dissociation constant (K d ) of M pro dimerization is about 2 mM (6) and that is consistent to what we found in our work. Thus, M pro would be largely monomeric at 1.2 mM and dimeric at 18 mM. After exposure of 1.2 mM M pro to 2 mM GSSG, activity was inhibited by an average of 44%, while after exposure to 10 mM GSSG, activity was inhibited by more than 90% (Fig. 1A) . By contrast, GSH had little effect at these concentrations (Fig. 1A) . Interestingly, when the M pro concentration was increased to 18 mM, it was resistant to GSSG inhibition, with no inhibition observed with 2 mM GSSG and less than 20% inhibition with 10 mM GSSG (Fig. 1B) . These results suggest that monomeric M pro is more sensitive to glutathionylation than dimeric M pro . To confirm that M pro was becoming modified with GSSG under these conditions, we acidified the samples at the end of the enzyme assays with formic acid/trifluoroacetic acid (FA/TFA) to arrest activity and glutathionylation and analyzed them by RP-HPLC/MALDI-TOF MS. The extent of glutathionylation was assessed by determining the mass of M pro by protein deconvolution and by looking for the addition of approximately 305 atomic mass units (amu) and/or multiples of 305 to M pro , consistent with the addition of glutathione(s) via a disulfide bond. As revealed by RP-HPLC/MALDI-TOF MS analysis, treatment of 1.2 mM M pro with 2 mM GSSG led to an estimated 45% monoglutathionylation (estimate based on the mass abundances), whereas treatment with 10 mM GSSG led to mono-(11%), di-(50%), and triglutathionylation (35%), with less than 4% of M pro remaining unmodified (Fig. 1C ). Comparing the results of Fig. 1A with those from Fig. 1C , the inhibition of M pro activity closely correlated with the extent of glutathionylation. Although we found some variation in the extent of inhibition of M pro by GSSG when using different preparations of M pro , the extent of inhibition always correlated with the extent of modification with glutathione. Interestingly, the data obtained with 2 mM GSSG suggested that modification of only one cysteine may be sufficient to lead to inhibition of M pro activity, as this treatment yielded about 45% monoglutathionylation and little di-or triglutathionylation and showed an average 40% decrease in activity. By contrast, M pro incubated at 18 mM during treatment with 2 mM GSSG revealed little reduction in activity and only small amounts of glutathionylation ( Fig. 1B and D) . Moreover, treatment of 18 mM M pro with 10 mM GSSG led to only 14% monoglutathionylation (Fig. 1D) , which was associated with an average inhibition of 18% (Fig. 1B) , while no modification of M pro occurred in the presence of 2 mM or 10 mM GSH (see Fig. S2A and S2B in the supplemental material).

To better understand the nature of M pro inhibition by glutathionylation, we modified 1.5 mM M pro with 10 mM GSSG at pH 7.5 so that nearly all the M pro was modified with at least one glutathione. Excess GSSG was removed by washing through an Amicon 10-kDa-cutoff membrane. RP-HPLC/MALDI-TOF MS analysis of this preparation on a C 18 column followed by protein deconvolution indicated M pro was now a mixture of mono-(23%), di-(68%), and triglutathionylated forms (9%) with little detectable unmodified M pro (Fig. 1E ). To determine whether the modification was reversible with thiol reducing agents, we treated glutathionylated M pro with 10 mM dithiothreitol (DTT) for 30 min. This resulted in more than 90% of the glutathionylated M pro being converted back to native M pro (Fig. 1F) . We then tested the activity of these preparations of M pro . Glutathionylated M pro had less than 5% of the activity of unmodified M pro , confirming that glutathionylation was inhibiting protease activity (Fig. 1G) . Following the addition of 10 mM DTT, the activity was fully restored, while DTT marginally improved native M pro activity (Fig. 1G) . Glutathionylation of M pro inhibits M pro dimerization. To assess M pro dimerization, we established a method consisting of size exclusion chromatography (SEC) coupled to mass spectrometry (MS) like that described previously for HIV-1 protease (12) . We initially used SEC3000 columns and later SEC2000 columns from Phenomenex; both could be used successfully to separate M pro . When injected at 60 mM on a SEC3000 column, unmodified M pro eluted at 8.8 min ( Fig. 2A, black tracing) , while glutathionylated M pro eluted at 9.2 min ( Fig. 2A, red tracing) . When unmodified M pro was injected at 7.5 mM, it clearly eluted as two peaks at 8.9 and 9.4 min consistent with a monomerdimer behavior (Fig. 2B, black tracing) , while the glutathionylated M pro still eluted at 9.4 min consistent with a single species behavior (Fig. 2B, red tracing) . Deconvolution of the eluting M pro in Fig. 2A and B confirmed the expected masses for unmodified M pro ( Fig. 2C and E, black tracings) and the glutathionylated forms of M pro ( Fig. 2D and F, red tracings). Thus, the unmodified M pro had a typical monomer/dimer two-species system running as dimers at high concentrations (60 mM) and as dimers and monomers at lower concentrations (7.5 mM). Dimerization of native M pro was dependent on concentration, while glutathionylated M pro behaved as a single monomer-like species independent of its concentration. Matched native and glutathionylated M pro samples (18 mM) were analyzed by analytical ultracentrifugation (AUC) to obtain both the molecular mass of the species and the K d for dimerization. The results indicated that native M pro was in equilibrium between monomeric and dimeric forms and behaved with a calculated dimerization K d of 2.4 mM (Fig. 2G) , consistent with previous reports (6) . At high concentrations (60 mM), M pro was almost completely dimeric (Fig. 2G ). By contrast, under the same conditions, the glutathionylated M pro behaved almost completely monomeric with an estimated K d of 200 mM (Fig. 2H) , indicating that glutathionylation was interfering with dimerization of M pro .

Modification of a single cysteine of M pro leads to inhibition of dimerization and activity. To determine whether glutathionylation of a single cysteine might render the enzyme monomeric and inactive, we generated a glutathionylated M pro preparation by exposing 1.2 mM M pro to 5 mM GSSG at pH 6.8, a pH that would favor the glutathionylation of only the most reactive cysteines (with low pK a s). This monoglutathionylated preparation had approximately 35% monoglutathionylated M pro (see Fig. S3A in the supplemental material). We then analyzed the preparation (8 mM) by size exclusion and used MALDI-TOF MS detection to determine where the masses for monoglutathionylated and native M pro eluted (using protein deconvolution). This glutathionylated preparation ran as two peaks consistent with the presence of both dimeric and monomeric forms of M pro (Fig. 3A) . Deconvolution of these two peaks revealed the elution profile for monoglutathionylated M pro (Fig. 3B ) and the elution profile for native M pro FIG 1 Legend (Continued) was assayed for protease activity at an equal final enzyme concentration (1 mM). In panels A and B, the values shown are the means 6 standard deviations (error bars) for three independent experiments (n = 3) (***, P value of ,0.005, paired Student's t test). All other comparisons to control (Ctl) activity were not found to be significant (P value of .0.05). M pro control activity for panel A was 6.42 6 2.5 mM/min/mg, and for panel B, it was 9.6 mM/min/mg, and the percent activity of the treatment was normalized to that of their respective control. ns, not significant. (C and D) Molecular masses found by protein deconvolution for control and GSSG-treated M pro eluting from a C 18 reverse-phase column after treatment of 1.2 mM (C) and 18 mM (D) M pro . The theoretical molecular mass of M pro is 33,796.48, and the deconvoluted molecular masses for controls in panels C and D were 33,797.09 and 33,797.34, respectively, as determined using Agilent's Mass Hunter software. The experimental masses are shown above each peak. The native M pro as well as the increases in mass indicative of glutathionylation are indicated for the addition of one (1 -sG), two (2 -sG), and three (3 -sG) glutathione moieties in the deconvolution profiles of GSSG-treated M pro . The observed mass increases were 304, 609, and 913 compared to the predicted increases of 305.1, 610.2, and 915.3 for the addition of one, two, or three glutathiones, respectively. Based on the abundances, the estimated percentage of monoglutathionylation in panel C at 2 mM GSSG was 45%, and for 10 mM GSSG, there was an estimated 11% mono-, 50% di-, and 35% triglutathionylation, respectively. (D) After treatment with 2 mM GSSG, there was ,5% monoglutathionylation, and with 10 mM GSSG, there was an estimated 34% monoglutathionylation. (E and F) M pro (1.5 mM) was glutathionylated (Glut) at pH 7.5 with 10 mM GSSG, and then excess GSSG was removed by Amicon filtrations as described in Materials and Methods. The extent of glutathionylation was determined by RP-HPLC/MALDI-TOF MS before (E) and after (F) treatment with 10 mM DTT (30 min). Shown above each peak is the molecular mass (top number) and the abundance (bottom number). ( Fig. 3C) . Interestingly, the mass for monoglutathionylated protease eluted from the size exclusion column predominantly (.70% of the total area) in the second peak, consistent with it behaving primarily as a monomer (Fig. 3B) , while native M pro eluted as both dimers and monomers as expected at this concentration ( Fig. 3C and see Fig. 2B ). Treatment of the glutathionylated M pro preparation with reducing agent [Tris (2-carboxyethyl) phosphine hydrochloride (TCEP)] to remove the glutathione moiety led to an increase in the dimer peak and decrease in the monomer peak (see Fig. S3A and S3B in the supplemental material). Deconvolution revealed only the mass corresponding to native M pro eluting across both dimeric and monomeric peaks (see Fig. S3B in the supplemental material). We also collected the first and second peaks eluting from SEC analysis of the monoglutathionylated preparation (peaks 1 and 2, labeled in Fig. 3A ) and tested them for M pro activity at equal protein concentrations. The activity of the second peak was only 25% of that of the first peak, consistent with monoglutathionylation causing the protease to elute primarily as a monomer and inhibiting M pro activity (P , 0.01) (Fig. 3D ). Treatment of the second peak with TCEP to remove the glutathione moiety, resulted in a significant increase in activity (P , 0.01) while having no significant effect (P . 0.05) on the activity of first peak (Fig. 3D ). These data provide strong evidence that monoglutathionylated M pro behaves as an inactive monomer and that dimerization potential and activity can be restored by removing the modification.

Inhibition of M pro activity by glutathionylation is reversible with glutaredoxin (Grx). Grx (also known as thioltransferase) is a ubiquitous cellular enzyme that can reverse glutathionylation of many cellular proteins. We tested whether Grx could deglutathionylate M pro and restore its activity. Preparations of glutathionylated M pro were prepared at pH 6.8 (to predominantly modify the most reactive cysteines) or pH 7.5 and tested for reversibility of glutathionylation and restoration of activity following treatment with Grx. The glutathionylated preparation made at pH 7.5 contained no detectable unmodified M pro and was predominantly diglutathionylated M pro (75%) and monoglutathionylated (22%) with the remainder triglutathionylated (3%) (Fig. 4A) . Incubation of the preparation with 0.5 mM GSH alone, a cofactor required for Grx activity, produced a small amount of detectable unmodified M pro (1.5%) and minor changes in percentages of other forms of M pro (compare Fig. 4A with Fig. 4B ). However, incubation of glutathionylated M pro with Grx and 0.5 mM GSH resulted in loss of the triglutathionylated M pro , a substantial decrease in diglutathionylated M pro (from 75% to 16%), and an increase in monoglutathionylated M pro (22% to 65%) and native M pro which made up 19% of the total M pro (Fig. 4C ). M pro activity was then assessed under these same conditions. Incubation of glutathionylated M pro with 350 nM Grx in the presence of 0.5 mM GSH led to a significant increase in protease activity, restoring an average 58% of the activity compared to untreated M pro , while 0.5 mM GSH alone restored only about 10% of the activity (Fig. 4D) . We also assessed the ability of Grx to restore activity of the monoglutathionylated preparation made at pH 6.8. The glutathionylated preparation used in these experiments contained approximately 32% monoglutathionylated M pro based on percent abundance and 4% diglutathionylated with the remainder (64%) unmodified. Incubation of this preparation of M pro with 350 nm Grx with 0.5 mM GSH for just 5 min increased M pro activity from 46% to 78% of control activity (Fig. 4E ). GSH alone increased activity to a lesser degree from 46% to 58% of the control (Fig. 4E ). In addition, Grx in a dose-dependent manner was able to deglutathionylate Identification of glutathionylated cysteines by MALDI-TOF MS. To determine which cysteines of M pro are responsible for inhibition of dimerization and activity, we digested native M pro and a monoglutathionylated preparation of M pro (containing approximately 35% monoglutathionylated forms of M pro ) with chymotrypsin or a combination of trypsin/lysC to produce peptides that could be assessed for glutathionylation. Prior to digestion, we alkylated free cysteines with N-ethylmaleimide (NEM) using the AccuMAP System (Promega); this step limits disulfide scrambling during alkylation and proteolytic digestion processes. From chymotrypsin digestions of native M pro which was fully alkylated with NEM, we were able to identify alkylated peptides for 7 of the 12 cysteines of M pro , including cysteines 38, 44, 117, 128, 145, 156, and 300 by MS (see peptides 1 to 10 in Table S1 in the supplemental material) along with 12 other noncysteine peptides (see peptides 15 to 26 in Table S1 in the supplemental material). To identify which cysteines were becoming glutathionylated, we searched for predicted glutathionylated monoisotopic masses by molecular ion extraction of the total ion chromatogram (TIC) obtained from RP-HPLC/MALDI-TOF MS analysis of chymotrypsin digests. We located monoisotopic masses consistent with three glutathionylated peptides: 151 NIDYDC GSH VSF 159 , 295 DVVRQC GSH SGVTF 305 , and 295 DVVRQC GSH SGVTFQ 306 with glutathionylated Cys 156 , Cys 300 , and Cys 300 , respectively (Table 1 ; also see Fig. S5A to S5J for detailed analysis in the supplemental material). To confirm these peptides were, indeed, glutathionylated forms of the predicted M pro native peptides, we analyzed the peptide digests after treatment with TCEP to remove disulfide-bound glutathione. When this was done, the masses for all three of the predicted glutathionylated peptides were no longer detected, due to the removal of glutathione with TCEP, and in its place we were able to locate the predicted native masses expected following removal of glutathione for all three peptides (Table 1 and see Fig. S5K to S5P in the supplemental material). These results demonstrated that Cys156 and Cys300 are both glutathionylated at pH 6.8 using GSSG modification (see Fig. S5 in the supplemental material).

Due to the inability to assess modification of cysteines 16, 22, 85, 161, and 265 using the chymotrypsin data, as the peptides carrying these residues were not located (see Table S1 for a list of the peptides found, in the supplemental material), we prepared trypsin/lysC digests of native M pro and the same monoglutathionylated M pro preparation used in chymotrypsin experiments. Using this approach, we were able to evaluate cysteines 16, 22, 85, and 265 (see Table S2 for a list of the peptides found, in the supplemental material). Interrogation of the TIC chromatogram for masses corresponding to glutathionylated forms of cysteine-containing peptides following tryspin/ lysC digestion, revealed masses consistent with glutathionylation of three peptides: 77 VIGHSMQNC GSH VLK 88 , 299 QC GSH SGVTFQ 306 and 299 pyQC GSH SGVTFQ 306 (the pyroglutamate (py) form of the 299-306 peptide which results from spontaneous deamidation of peptides with N-terminal glutamyl residues [23] ) ( Table 2 and see Fig. S6A to S6J in the supplemental material). These were glutathionylated at Cys 85 , Cys 300 , and Cys 300 , respectively (Table 2) . Also, as with chymotrypsin digestion, the calculated masses for the three native forms were found following analysis of the tryptic digests after reduction with TCEP (Table 2 and see Fig. S6E to S6P in the supplemental material). The data Regulation of SARS-CoV-2 Main Protease ® from the trypsin/lysC digestion indicated that the majority of the monoglutathionylation was occurring at Cys300. We based this on the greater area at 205 nm obtained for glutathionylated Cys300 peptides than the Cys85 peptide (combined area for glutathionylated Cys300 peptides at 205 nm was 301 versus 56 for the glutathionylated Cys85 peptide) and their native forms (combined area at 205 nm for native Cys300 peptides was 272 versus 21 for the native Cys85 peptide) (see Fig. S6C and S6D in the supplemental material). Importantly, in all cases, the differences between the experimental and calculated peptide masses were less than 0.05 amu, providing strong confidence in their identity (Tables 1 and 2) .

Together, the two approaches could identify peptides containing all cysteines of M pro, except for Cys161. The combined data obtained from the chymotryptic and tryptic/lysC digestions of M pro and glutathionylated M pro showed that Cys85, Cys156, and Cys300 were glutathionylated. The trypsin/lysC 205-nm analysis provided evidence that only a minority of the glutathionylation was occurring at Cys85 (a similar analysis could not be done for Cys156 because of overlapping peaks in the chymotrypsin digests). Given the effects of glutathionylation on activity and dimerization and the importance of amino acids 298 and 299 for dimerization (4, 7) , it suggested that Cys300, located at the dimer interface, is a primary target for glutathionylation of M pro in its monomeric state and responsible for the effects we observed. Cys300 is required for inhibition of M pro activity following glutathionylation.

To determine whether Cys300 was, in fact, the principal contributor to the inhibition of activity of M pro following glutathionylation, we prepared a C300S mutant M pro (for purity and molecular weight analysis, see Fig. S1F to S1I) and evaluated the effects of glutathionylation on M pro activity. We noted that the basal activity of M pro C300S was about 50% that of WT M pro . After 30 min of treatment at 1.2 mM with 10 mM GSSG, the activity of WT M pro was inhibited by more than 50%. By contrast, this treatment did not affect the activity of C300S M pro (Fig. 5A) . We also measured the extent of glutathionylation for WT and C300S M pro following the enzyme assay. On the basis of the absolute abundances of each form, we found that WT M pro had 46%, 14%, and 5% mono-, di-, The retention times (RT) and molecular masses for the Cys300 peptides were confirmed with the use of synthetic peptides that were run on RP-HPLC/MALDI-TOF as native, alkylated, or glutathionylated peptides. Following trypsin/lysC digestion, the peptide samples were analyzed in the absence (2) or presence (1) of 50 mM TCEP to remove glutathione moieties from the digested peptides. The calculated (Calc.) native masses (M r ), the experimental (Expt.) masses, and the difference in mass (D) for each peptide are shown. b A GSH superscript after Cys indicates modification of cysteine by glutathione based on a monoisotopic mass increase of approximately 305 amu (expected 305.08 amu). c These peptides are the result of the spontaneous deamidation that occurs with peptides containing an Nterminal glutamyl residues (23) , and the retention times and molecular masses for this peptide were confirmed with the use of synthetic peptides that were run on RP-HPLC/MS. and triglutathionylated forms, respectively, with the remainder (35%) unmodified, while after the same treatment, C300S had 36% and 11% mono-and diglutathionylated forms, respectively, with the remainder (53%) unmodified. This indicated that while almost 50% of C300S could still become glutathionylated at other cysteine residues (possibly Cys85 and Cys156), its activity was unaffected, strongly implicating Cys300 in the inhibition of M pro activity following glutathionylation of WT M pro . To determine whether Cys300 was the primary target for glutathionylation when incubating with GSSG at the lower pH of 6.8, we treated WT and C300S M pro with 5 mM GSSG at pH 6.8 for 2.5 h to produce monoglutathionylated forms of M pro . Based on SEC/ MALDI-TOF MS analysis, the WT M pro was 36% glutathionylated, while the C300S M pro was only 16% glutathionylated based on the abundances for each form (Fig. S7E and  S7F) . These data suggest that there are at least two reactive cysteines under these lower pH conditions. Activity of these preparations was measured before and after reduction with DTT. DTT increased the activity of the monoglutathionylated WT M pro preparation by 26% but had no significant effect on the activity of monoglutathionylated C300S M pro mutant (Fig. 5B ). This suggests that while the C300S mutant can still become glutathionylated at alternative cysteines, the modification has little effect on M pro activity.

GSSG is commonly used to probe the selective susceptibility of protein-cysteine residues to S-glutathionylation, as we have done here. However, to simulate intracellular oxidative stress conditions associated with viral infection, we also treated the M pro protein with H 2 O 2 in the presence of physiological relevant levels of GSH to represent the production of ROS in the normally reducing environment of the cell. We found that H 2 O 2 in the presence of GSH promoted selective S-glutathionylation of WT-M pro versus M pro -C300S, analogous to what we observed with GSSG (see Fig. S8A and S8B in the supplemental material).

In cells that are under oxidative stress, cellular and foreign proteins may undergo glutathionylation, and this process, which is reversible, can alter the function of these proteins (20, (24) (25) (26) (27) . Some notable cellular proteins glutathionylated in vivo include Ras, beta-actin, IKK-beta, PTP1B, and caspase-3 (for reviews, see references 20 and 27). In this work, we found that dimerization and activity of M pro can be regulated through reversible glutathionylation of Cys300 as depicted in our model in Fig. 6A . Cys85, Cys156, and Cys300 underwent measurable glutathionylation even at pH 6.8. However, only a minor amount of glutathionylation occurred at Cys85, and while Cys156 and Cys300 are both surface-exposed residues (Fig. 6B) , we further investigated Cys300 due to its unique location at the dimer interface ( Fig. 6B and C) . Although there are numerous roles this regulatory system could play during SARS-CoV-2 replication in host cells under oxidative stress, it has nonetheless revealed a reactive cysteine that provides a novel target for the development of M pro inhibitors that could be used to block SARS-CoV-2 replication.

A number of proteins have been shown to undergo glutathionylation in cells undergoing oxidative stress, and biochemical studies with GSSG, as performed here, can inform our understanding as to whether reversible glutathionylation might regulate the activity of key proteins (27) . However, glutathionylation of proteins within cells undergoing oxidative stress is thought to more often go through sulfenic acid intermediates formed in the presence of H 2 O 2 acting on susceptible thiols (27) . Several reports have shown that studies in which proteins are exposed to 200 to 1000 mM H 2 O 2 in the presence of GSH can provide insights on the glutathionylation of these proteins in cells undergoing oxidative stress (see, for example, references 28 and 29). In addition to the experiments performed with GSSG, we have also demonstrated that exposure of M pro to GSH in the presence of physiologically relevant concentrations of H 2 O 2 (28, 29) results in glutathionylation and that the degree of glutathionylation is about 50% less with C300S. With this background, the results here provide evidence to suggest that M pro is reversibly glutathionylated in cells undergoing oxidative stress.

Glutathionylation of proteins occurs via a mixed disulfide between glutathione and a cysteine residue. Most cysteine residues have relatively high pK a s (pH 8.0 or greater) and usually remain protonated under physiological conditions, making them relatively unreactive at typical cellular pH. However, studies have shown that the local environment around certain cysteine residues can lower their pK a , making them more susceptible to oxidation and glutathionylation (30) (31) (32) . The local environment of Cys300 may account for this susceptibility to glutathionylation, and this provides a means to selectively target this cysteine residue with inhibitors. Previous studies have found that basic residues or serine hydroxyl sidechains in the local environment can substantially reduce the pK a of thiols (30, 33) . As for Cys300, there is a basic residue at Arg298 and a hydroxyl residue at Ser301. This may increase the local acidity of the Cys300 thiol group in the monomeric state, making it more prone to oxidation, while in the dimeric state, Arg298 is involved in interactions which stabilize the dimer (7). Inspection of a previously determined monomeric form of SARS-CoV-1 M pro (R298A) reveals that the carbonyl side chains of Asn214 and Gln299, which can act as hydrogen acceptors and potentially destabilize the thiol group, show close contact with the Cys300 thiol (Fig. 7) ; this may enhance its reactivity. Although there is not a monomer structure of SARS-CoV-2 M pro , the distances of the Cys300 thiol to the carbonyls in SARS-CoV-1 and -2 dimer are much greater, possibly decreasing the reactivity of the dimeric form (see Fig. S8C and S8D in the supplemental material). Why have SARS-CoV-2 and other RNA viruses evolved to have a dimeric protease susceptible to reversible inactivation by glutathionylation of a cysteine at the dimer interface? It is possible that this serves to blunt viral processing and replication in cells undergoing significant oxidative stress, which otherwise may generate defective viral particles (34) . Also, high levels of M pro are toxic to cells (35) , and it is possible that this mechanism evolved to inactivate M pro after cleavage by M pro has released the viral proteins needed for replication as a result of virus-induced oxidative stress. Thus, Cys300 may act to regulate M pro activity during viral replication to optimize the generation of new virions without prematurely killing the host cell. Moreover, M pro from SARS-CoV-1 and SARS-CoV-2 contain 12 cysteines and 10 methionine residues. Studies have shown that such residues can also act as decoys to prevent permanent damage to proteins during oxidative stress (36, 37) . In the case of M pro , this could help protect the active site cysteine required for catalysis. It should be noted that the details of the initial autocatalytic processing of M pro from the polyproteins pp1a and pp1ab are still not fully understood, but in the case of HIV, we have shown that similar oxidative modifications can also reversibly inhibit the initial autocleavage of the Gag-Pol-Pro polyprotein, and this may similarly be true for autocleavage of M pro from the polyproteins (8, 9, (11) (12) (13) 38) . There is evidence that this may also be the case with Mason Pfizer monkey virus polyprotein processing (39) .

It is interesting to speculate that this feature of coronavirus M pro may have relevance to its evolution. M pro from the three closest bat coronavirus relatives to SARS-CoV-2 (40) have an extremely high (.99%) degree of amino acid identity to that of SARS-CoV-2, and all three contain 12 cysteine residues, including Cys300. SARS-CoV-2 is thought to have jumped to humans from an original reservoir in Rhinolophus bats, possibly through an intermediate host (41) . Bats are reservoirs for a vast number of coronaviruses and other RNA viruses and are often infected with these viruses without showing any signs of disease (42) . One reason for this coexistence is that bats have evolved an immune response to RNA viruses with a minimal inflammatory response (42) . In addition, the act of flying requires considerable metabolic energy, and when in flight and during migration, bats are placed under high levels of oxidative stress (43) (44) (45) . Moreover, bats spend much of their lives in densely populated shelters such as caves that facilitate virus transmission. Not killing off the host bat colonies would appear to be a good evolutionary strategy for bat coronaviruses, and one can speculate that part of this evolutionary adaption might be dampening of viral replication under conditions of oxidative stress through the inhibition of M pro by glutathionylation.

A more practical implication of our findings is that it can inform the development of antiviral drugs against SARS-CoV-2. While vaccines are effective at preventing COVID-19, effective anti-SARS-CoV-2 drugs are urgently needed and will remain so for the foreseeable future. Because of its essential role in SARS-CoV-2 replication, M pro is an attractive target for drug development. Nearly all this effort has focused on active site inhibitors of M pro which can block SARS-CoV-2 replication and cytopathic effect (6, (46) (47) (48) (49) (50) (51) (52) . Although Regulation of SARS-CoV-2 Main Protease ® we carefully looked for glutathionylation of the active site cysteine, we could not confirm reversible glutathionylation occurring at Cys145. Our observation that Cys300 at the dimer interface is particularly susceptible to oxidative modification and that this modification can block dimerization of M pro , resulting in inhibition of activity, reveals an alternative way of targeting M pro . Being on the M pro surface in the monomer, this cysteine may be highly accessible and may thus be a promising target for the development of specific M pro inhibitors. In this regard, Günther and Reinke et al. (51) have recently identified the hydrophobic pocket consisting of Ile21, Leu253, Gln256, Val297, and Cys300 of SARS-Cov-2 M pro as an allosteric binding site for two different compounds (51) . Our results indicate that this area can be specifically targeted through Cys300, which is highly reactive and, if modified, leads to inhibition of dimerization.

Enzymes, peptides, and reagents. The substrate peptide for M pro (H2N-TSAVLQ-pNA) and peptides corresponding to several predicted chymotryptic fragments containing cysteine residues, including M pro peptides consisting of amino acids fragments 113:118, 127:134, 141:150, 155:159, 295:305 and 295:306 as well as the predicted tryptic fragment, 299:306, were obtained (.95% purity) from New England Peptide (Gardner, MA). Amicon ultracentrifugal filters (10-kDa cutoff, 0.5 ml, and 15 ml), carboxymethyl bovine serum albumin (cm-BSA), oxidized and reduced forms of L-glutathione (Bioxtra) (.98%), 4-nitroaniline (.99%), the reducing agents Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) and dithiothreitol (DTT) were from Sigma-Aldrich (Milwaukee, WI). BioSep SEC3000 and SEC2000 size exclusion columns (300 Â 4.6 mm) were from Phenomenex (Torrence, CA). The Vydac C 18 column (218TP5205) was from MAC-MOD Analytical (Chadds Ford, PA). Peptide desalting columns from ThermoFisher Scientific (Pittsburgh, PA) and AccuMap low-pH protein digestion kit (with trypsin and lysC) and chymotrypsin (sequencing grade) were from Promega (Madison, WI). PreScisson protease was from GenScript (Piscataway, NJ). Recombinant human glutaredoxin (Grx) transcript variant 1 was from Origene (catalog no. TP319385) (Rockville, MD) and stored at 270°C in 25 mM Tris-HCl (pH 7.3), 100 mM glycine, and 10% glycerol (7 mM stock).

Expression and purification of authentic M pro and C300S M pro . The SARS-CoV2 M pro -encoding sequence and C300S mutant sequence were cloned into pGEX-4T1 vector (Genscript) with N-terminal self-cleavage site (SAVLQ/SGFRK) and C-terminal His 6 tag as previously designed by others (6) . The plasmid constructs were transformed into BL21 Star (DE3) cells (ThermoFisher Scientific). The cultures were grown in terrific broth medium supplemented with ampicillin (Quality Biological, Gaithersburg, MD). At an optical density at 600 nm of 0.8, the cultures were induced by adding 1 mM isopropyl-a-D-thiogalactopyranoside and maintained at 20°C overnight. SARS-CoV2 M pro and C300S M pro were purified first by affinity chromatography using Talon cobalt-based affinity resin (TaKaRa Bio). The His 6 tag was cleaved off by PreScission protease, and the resulting authentic 306-amino-acid M pro (see Fig. S1A in the supplemental material) and C300S M pro were further purified by SEC using a HiLoad Superdex 200 pg column (GE Healthcare) in 20 mM Tris (pH 7.5), 150 mM NaCl, and 2 mM DTT. The purity and molecular mass of M pro were assessed by lithium dodecyl sulfate (LDS) gel electrophoresis as well as reverse-phase highperformance liquid chromatography (RP-HPLC) on a C 18 column coupled with a matrix-assisted laser desorption ionization2time of flight (MALDI-TOF) mass spectrometer (MS). The purity of these M pro s was greater than 95% by LDS gel electrophoresis, RP-HPLC chromatography (205 nm), and MALDI-TOF MS analysis (see Fig. S1B to S1D and S1F to S1H in the supplemental material), with an average experimental mass of 33,796 amu 6 1 amu for WT (expected average mass of 33,796.48 amu) (see Fig. S1E and inset in the supplemental material) and an average experimental mass of 33,781.8 for C300S (expected average mass of 33,780.40 amu) (see Fig. S1I and inset in the supplemental material). The final preparations of M pro (2 to 6 mg/ml) were stored at 270 in 40 mM Tris-HCl buffer (pH 7.5), 2 mM DTT, and 150 mM NaCl.

M pro colorimetric enzyme assay. The enzymatic activity of M pro of SARS-CoV-2 was measured using the custom-synthesized peptide H2N-TSAVLQ-pNA as described previously (21, 22) . TSAVLQ represents the nsp4;nsp5 cleavage sequence for SARS-CoV-1 and SARS-CoV-2 M pro . The rate of enzymatic activity was determined by following the increase in absorbance (390 nm) using a Spectramax 190 multiplate reader at 37°C as a function of time following the addition of substrate. Assays were conducted in clear flat bottom 96-well plates (Corning) in a total volume of 50 ml. Assays consisted of 40 ml of assay buffer (50 mM Tris [pH 7.5], 2 mM EDTA, and 300 mM NaCl containing 100 mg/ml of cm-BSA). Reactions were started by the addition of 10 ml of 2 mM substrate dissolved in ultrapure water and warmed to 37°C. Activity was obtained by measuring the increase in absorbance at 390 nm as a function of time within the linear range of the assay. A calibration curve was obtained for the product, 4-nitroanaline (pNA), and was used to convert the rate of the reaction to units of micromoles of product per minute per milligram of protein. In some cases, activity and M pro modifications were determined by first stopping the assay at a set time (5 min) by acidification with formic acid (FA)/trifluoroacetic acid (TFA) and then analyzed by RP-HPLC using a 2% acetonitrile gradient on a Vydac C 18 column as described below. The activity was calculated based on the amount of pNA product generated (detected at 390 nm) following RP-HPLC analysis.

Glutathionylation of M pro at pH 7.5 and pH 6.8. To prepare glutathionylated M pro for use in analytical ultracentrifugation, size exclusion chromatography (SEC), and activity assays, M pro was first exchanged into a buffer containing 40 mM Tris-HCl, 2 mM EDTA, and 300 mM NaCl at pH 7.5 using Amicon 10-kDa-cutoff filter units. M pro (1.5 mM) was then treated only with buffer or with a final concentration of 10 mM GSSG diluted from a stock of 200 mM GSSG that had been adjusted to neutral pH with sodium hydroxide. The solutions were then incubated at 37°C for 60 min or otherwise as described in Results before removing excess GSSG. To remove excess GSSG, the preparations were diluted 10Â with buffer (50 mM Tris-HCl, 2 mM EDTA, and 100 mM NaCl) and washed four times using Amicon 10-kDa-cutoff filter units (0.5 ml). The final preparations were concentrated further with a 0.5-ml 10-kDa filtration unit (0.6 mg/ml). In some cases, these preparations were concentrated to 2 to 6 mg/ml for use in SEC. While the extent of glutathionylation varied among preparations of M pro , the procedure done at pH 7.5 usually yielded preparations of M pro that contained predominantly diglutathionylated M pro based on mass spectrometry (MS) deconvolution analysis as well as monoglutathionylated and triglutathionylated forms. To modify Mpro more selectively with GSSG, a similar procedure to that above was used except 5 mM GSSG was used and we lowered the buffer pH to 6.8. This pH was used to favor reaction of the most reactive cysteines (those cysteines whose pK a may be lower than expected). Prior to modification, M pro was treated with 50 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) for 30 min to ensure all cysteines were in their reduced form, and then TCEP was removed by multiple washes through an Amicon 10-kDa-cutoff filter with pH 6.8 incubation buffer (50 mM Tris-HCl, 2 mM EDTA, and 100 mM NaCl). For glutathionylation, M pro (1.2 mM) was incubated for 2.5 h at 37°C in 50 mM Tris-HCl buffer, 300 mM NaCl, and 2 mM EDTA at pH 6.8 with either buffer only or 5 mM GSSG. The preparations were then washed four times to remove excess GSSG using Amicon 10-kDa-cutoff filter units (0.5 ml) with pH 6.8 buffer. This procedure typically resulted in 30 to 40% of M pro becoming monoglutathionylated with less than 10% diglutathionylated. The percentage of the glutathionylated M pro forms was estimated based on the abundances of the different protein forms (obtained by protein deconvolution). Although these modified forms of M pro are not drastically different in molecular weight (differences of 305 and 610 amu, for example), they could have somewhat different ionization potentials, and therefore, the numbers are only an estimate of percent modification.

To confirm the identity of certain peptide fragments, we purchased synthetic peptides and modified them accordingly and determined their masses and retention times on the RP-HPLC/MS analysis. Peptides (100 mM) corresponding to chymotryptic fragments from digested M pro (113:118, 127:134, 141:150, 155:159, and 295:305) were glutathionylated with 10 mM GSSG in 50 mM Tris-HCl buffer, 300 mM NaCl, and 2 mM EDTA (pH 7.5) for 1 h. These same peptides as well as 295:306 and the tryptic peptide 299:306 were alkylated with 5 mM N-ethylmaleimide (NEM) for 30 min at 37°C and then acidified to a pH of less than 3.0 with formic acid. Glutathionylation and NEM alkylation of the peptides was verified using RP-HPLC/TOF MS analysis on a Vydac C 18 column with the same method that was used for analysis of trypsin/lysC and chymotrypsin digests of M pro as described below.

Grx assays on glutathionylated forms of M pro . To determine whether Grx could deglutathionylate M pro , monoglutathionylated preparations of M pro containing 30 to 40% monoglutathionylated or multiglutathionylated M pro (prepared as described above in "Glutathionylation of M pro at pH 7.5 and pH 6.8") (8 mM) were used. For preparations made at pH 7.5 which had predominantly diglutathionylated M pro , the preparation was incubated at 37°C for 30 min in the presence of buffer control (50 mM Tris [pH 7.5], 2 mM EDTA, and 100 mM NaCl containing 100 mg/ml of carboxymethyl bovine serum albumin [cm-BSA]), Grx (350 nM) alone, GSH alone (0.5 mM), and Grx and GSH together. The samples were then analyzed for M pro activity and by SEC3000/MALDI-TOF MS to assess the different forms of M pro . The eluting protease was analyzed by protein deconvolution (8.3 to 10 min) to determine the M pro species present. Experiments with monoglutathionylated preparations made at pH 6.8 were also performed using GSH at 0.1 mM. In this case, the monoglutathionylated M pro preparation was incubated for 15 min at 37°C in 50 mM Tris (pH 7.5), 2 mM EDTA, and 100 mM NaCl containing 100 mg/ml of cm-BSA, Grx (88 to 350 nM), 0.1 mM GSH, or 0.1 mM GSH with 88 to 350 nM Grx in a total volume of 10 ml. After incubation, an aliquot of each sample was assayed for M pro activity (1 mM) and analyzed (2 ml) by SEC/MALDI-TOF MS to determine the percentage of glutathionylation in each treatment based on the abundances of each species. For these experiments, the enzyme activity was assessed after stopping the reactions by acidification with FA/TFA and determining the pNA product produced using RP-HPLC, as described above, to quantitate the amount of pNA product generated over the 5-min incubation. TCEP-treated glutathionylated enzyme was used to obtain the maximum native M pro activity.

Chymotrypsin and trypsin/lysC digestion and analysis of native and glutathionylated M pro . Native M pro and M pro which was monoglutathionylated (;30% to 40%) at pH 6.8 as described above was digested with chymotrypsin or trypsin/lysC using the Accumap low-pH sample preparation with urea under nonreducing conditions (Promega). The free cysteines in the M pro preparations (100 mg) were first alkylated with N-ethylmaleimide in 8 M urea for 30 min at 37°C. Complete alkylation of all cysteines of the native M pro with NEM was verified by RP-HPLC/TOF MS analysis. For chymotrypsin digestion, the alkylated proteins were diluted to 1 M urea with 100 mM Tris and 10 mM CaCl 2 buffer (pH 8.0) (50 mg of protease in 57 ml added to 456 ml of buffer) and treated with 2.5 mg of chymotrypsin made fresh in 1 mM HCl. Samples were incubated overnight (18 h) at 37°C before stopping the reactions with a final concentration of 2% TFA to reach a pH of ,3.0. For trypsin/recombinant lysC digestions, the alkylated proteins were digested with low-pH resistant lysC for 1 h at 37°C followed by continued digestion with AccuMAP modified trypsin and AccuMAP low-pH resistant lysC for 3 additional hours, as described in the AccuMAP protocol. The peptide digests were then desalted using peptide desalting columns (ThermoFisher) following the manufacturer's instructions. The desalted clarified peptide mixtures were then dried in a Thermo speed vacuum system and resuspended in RP-HPLC solvent A (water with 0.1% FA and 0.02% TFA [0.1% FA/0.02% TFA]). Aliquots of the peptide digests were then analyzed without or with TCEP-Cl treatment (50 mM) to remove glutathione modifications and then were separated on a Vydac C 18 column. For peptide analysis, the starting conditions were 100% solvent A (water with 0.1% FA/0.02% TFA). Elution of peptides was done with a 1%/min solvent B (acetonitrile with 0.1% FA/0.02% TFA) gradient over the first 20 min followed by a 2%/min gradient over the next 10 min. The elution of peptides was monitored using UV absorbance at 205, 254, and 276 nm as well as MALDI-TOF MS detection. Peptide digests were analyzed before and after TCEP treatment (for native M pro , see Fig. S6A and Fig. S6B for UV and TIC chromatograms, respectively; for monoglutathionylated M pro digests without TCEP treatment, see Fig. S6C and Fig. S6D for UV and TIC chromatograms, respectively; for samples treated with TCEP, see Fig. S6E and Fig. S6F for UV and TIC chromatograms, respectively). Chymotrypsin digestion of alkylated M pro is predicted to produce 10 alkylated cysteine-containing peptides in addition to 12 other non-cysteine-containing peptides of 3 amino acids or more. The predicted monoisotopic molecular masses for these peptides and their glutathionylated forms were used to extract specific peptide ions from the TIC chromatograms, and the masses found were further confirmed by monoisotopic deconvolution. When glutathionylated masses were found, we then searched for the native counterparts following TCEP reduction. We could locate 6 of the 10 predicted alkylated cysteine-containing peptides (covering 7 of the 12 cysteines) following chymotrypsin digestion of M pro (see Table S1 for a list of peptides found in the supplemental material). In addition to the predicted cysteine-containing peptides, based on chymotrypsin digestion, the masses for two other cysteine-containing peptides were identified, including a 151:159 peptide fragment (containing Cys156) and a 305:306 peptide fragment (containing Cys300). These were produced, presumably, as a result of incomplete digestion by chymotrypsin at the 154:155 and 305:306 predicted cleavage sites (see Table S1 , 7b and 10b, respectively, in the supplemental material). We also found molecular masses consistent with 10 other non-cysteine-containing peptides generated by chymotrypsin digestion (see Table S1 in the supplemental material).

Trypsin/lysC digests were analyzed by RP-HPLC/MALDI-TOF MS for both native (see Fig. S8A for TIC chromatogram and Fig. S8B for UV chromatogram in the supplemental material) and monoglutathionylated preparations before (see Fig. S8C for TIC chromatogram and Fig. S8D for UV chromatogram in the supplemental material) and after TCEP treatment. Trypsin/lysC digestion is predicted to yield seven cysteine-containing peptides and five of the seven cysteine alkylated peptides were found by molecular mass extraction from the TIC obtained by RP-HPLC/MALDI-TOF MS (see Table S2 in the supplemental material). In addition to the predicted cysteine-containing peptides, the masses for two other cysteinecontaining peptides were identified including a 41:61 peptide, resulting from incomplete cleavage at the 60:61 trypsin cleavage site, and a mass consistent with the tryptic peptide 299:306 having undergone spontaneous formation of the pyroglutamate form of the peptide (see Table S2 in the supplemental material). This is commonly seen among peptides with N-terminal glutamates (23) , and its retention time and mass were confirmed using a synthetic peptide standard that contained both the native and pyroglutamate forms of the peptide.

RP-HPLC/TOF MS analysis. Samples from the colorimetric enzyme assay, as described above, were analyzed by RP-HPLC with an Agilent 1200 series chromatograph on a Vydac C 18 column (218TP5205, Hesperia, CA). Samples were injected (25 to 45 ml), and pNA substrate, pNA product, and native and modified forms of M pro were eluted with a 2%/min acetonitrile gradient beginning with 95% solvent A (0.1% FA)/0.02% TFA) in RP-HPLC/MS grade water and 5% solvent B (0.1% FA/0.02% TFA in acetonitrile). The 2% gradient continued for 30 min and then was ramped to 95% acetonitrile for 2 min followed by a 5-min reequilibration to the starting conditions. Elution of samples was monitored at 320 nm (for pNA substrate) and 390 nm (for pNA product) with an Agilent diode array detector followed by MS analysis with an Agilent 6230 time of flight MS configured with Jetstream. M pro and its glutathionylated forms eluted between 24 and 26 min (approximately 57% acetonitrile). The mass of the protein was determined by protein deconvolution using Agilent's Mass Hunter software. The TOF settings were the following: gas temperature, 350°C; drying gas, 13 liters/min; nebulizer, 55 lb/in 2 ; sheath gas temperature, 350°C; fragmentor, 145 V; skimmer, 65 V. The mass determination for peptides was done by deconvolution (resolved isotope) using Agilent Mass Hunter software (Agilent).

Analysis of M pro by SEC coupled with MALDI-TOF MS detection. Size exclusion chromatography (SEC) on native and glutathionylated forms of M pro was carried out using BioSep SEC3000 column and subsequently a BioSep SEC2000 column (300 mm  4.6 mm; Phenomenex, Torrance, CA, USA) with 25 mM ammonium formate running buffer (pH 8.0) on a 1200 series HPLC-MS system (Agilent, Santa Clara, CA, USA). The isocratic flow rate was 0.35 ml Á min 21 , and M pro samples were injected at 2 ml. Where indicated, cm-BSA was used as a carrier to help prevent nonspecific binding of protein during the analysis. Proteins eluting from the column were monitored using an Agilent 1100 series fluorescent detector connected in series with the Agilent 6230 TOF MS detector. At high concentrations, M pro eluted as a single peak with a tailing edge, while at lower concentrations, M pro eluted as two peaks consistent with it behaving as a monomer dimer system. For the SEC3000 column, the M pro peaks eluted between 8.5 and 10 min, while for the SEC2000 column, peaks eluted between 7 and 8.5 min. The percentage of different forms of M pro was estimated by using the abundances of each species which can provide only an estimate due to variations in ionization potential for each M pro species.

Analytical ultracentrifugation. For analytical ultracentrifugation (AUC), a Beckman Optima XL-I analytical ultracentrifuge, with absorption optics, an An-60 Ti rotor, and standard double-sector centerpiece cells, was used. Sedimentation equilibrium measurements of authentic native M pro and glutathionylated M pro were used to determine the average molecular weight and dissociation constant (K d ) for dimerization. M pro was diluted into 50 mM Tris (pH 7.5) buffer containing 2 mM EDTA and 300 mM NaCl buffer to 1 mM (6-ml total solution) and then was left untreated or was glutathionylated with 10 mM GSSG for 45 min in the same buffer. Both preparations were washed by passing through a 10-kDa-cutoff Amicon membrane and washing 4 times with 50 mM Tris buffer with 2 mM EDTA and 100 mM NaCl. The preparations were analyzed by RP-HPLC/MS, and the control contained native M pro , while the glutathionylated preparation had predominantly diglutathionylated protease (63%), as well as triglutathionylated protease (22%) and monoglutathionylated protease (15%) based on their relative abundances. There was no detectable native M pro remaining in this glutathionylated preparation. Proteins were concentrated to 0.6 mg/ml in 50 mM Tris buffer (pH 7.5) with 2 mM EDTA and 100 mM NaCl. Samples (100 ml) were centrifuged at 20°C at 21,000 rpm (16 h) and 45,000 (3 h) overspeed for baseline. Data (the average of 8 to 10 scans collected using a radial step size of 0.001 cm) were analyzed using the standard Optima XL-I data analysis software v6.03.

Statistical analysis. Statistical analyses were performed using two-tailed Student's t test (paired) on experiments with at least three biological replicates. P values of .0.05 were not significant (ns) and values less or equal to 0.05 were considered statistically significant.

Data availability. All data are available in the main article or in the supplemental material.

Supplemental material is available online only. 

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection

Characterization and inhibition of SARS-coronavirus main protease

Activation and maturation of SARS-CoV main protease

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Mechanism for controlling the dimermonomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease

Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation

Regulation of HIV-1 protease activity through cysteine modification

HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with Regulation of SARS-CoV-2 Main Protease ® methionine sulphoxide reductase

Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions

Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach

Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro

Reversible oxidation of HIV-2 protease

Ikkepsilon regulates viral-induced interferon regulatory factor-3 activation via a redox-sensitive pathway

Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production

Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury

Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression

Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review

Regulation by reversible S-glutathionylation: molecular targets implicated in inflammatory diseases

3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism

The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase

Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins

Inhibition of caspase-3 activity and activation by protein glutathionylation

The phosphatase activity of carbonic anhydrase III is reversibly regulated by glutathiolation

Posttranslational modification of cysteine in redox signaling and oxidative stress: focus on S-glutathionylation

Molecular mechanisms and clinical implications of reversible protein S-glutathionylation

Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase

Reactive oxygen species-induced stimulation of 5'AMP-activated protein kinase mediates sevoflurane-induced cardioprotection

Determinants of cysteine pKa values in creatine kinase and alpha1-antitrypsin

Reactivity of cysteine-67 of the human immunodeficiency virus-1 protease: studies on a peptide spanning residues 59 to 75

Reactivity of cysteine residues in the protease from human immunodeficiency virus: identification of a surface-exposed region which affects enzyme function

Evaluation of methods for the calculation of the pKa of cysteine residues in proteins

Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection

A simplified cell-based assay to identify coronavirus 3CL protease inhibitors

Methionine in proteins defends against oxidative stress

Cysteine residues exposed on protein surfaces are the dominant intramitochondrial thiol and may protect against oxidative damage

The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation

Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro

Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop

The proximal origin of SARS-CoV-2

Novel insights into immune systems of bats

Antioxidant defenses, longevity and ecophysiology of South American bats

High basal heat-shock protein expression in bats confers resistance to cellular heat/oxidative stress

Migratory flight imposes oxidative stress in bats

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors

Potential SARS-CoV-2 main protease inhibitors

Protease inhibitors targeting the main protease and papain-like protease of coronaviruses

Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2

We particularly thank Rodney L. Levine (National Heart, Lung and Blood Institute) for helpful guidance and discussions during this work.The We declare that we have no competing interests.